Antiretroviral Therapy - PAHO/WHO | Pan American Health …
WEBJun 28, 2021 · Antiretroviral therapy (ART) is treatment of people infected with human immunodeficiency virus (HIV) using anti-HIV drugs. The standard treatment consists of a combination of drugs (often called "highly active antiretroviral therapy" or HAART) that suppress HIV replication. The combination of drugs is used in order to increase potency …
Documents - PAHO/WHO | Pan American Health Organization
WEBJun 28, 2021 · Guidelines. 15 Mar 2023. Sentinel surveys of acquired HIV resistance to dolutegravir among people receiving dolutegravir-containing antiretroviral therapy. Technical and Scientific Products. 24 Nov 2021. HIV drug resistance report 2021. Technical Reports. 20 Sep 2021. Clinic-based survey of acquired HIV drug resistance.
HIV/AIDS - PAHO/WHO | Pan American Health Organization
WEBSep 30, 2024 · Antiretroviral therapy (ART) is treatment of people infected with human immunodeficiency virus (HIV) using anti-HIV drugs. The standard treatment consists of a combination of drugs (often called "highly active antiretroviral therapy" or HAART ) that suppress HIV replication.
Concept note: Surveillance of HIV drug resistance in adults ... - PAHO
WEBJul 7, 2014 · HIV Drug Resistance (HIVDR) emerges when HIV replicates in the presence of antiretroviral drugs. If HIV drug resistance becomes widespread, the drugs currently used to treat HIV infection may become ineffective. To date, levels of HIVDR in countries scaling up antiretroviral therapy (ART) remain manageable. However, resistance is slowly …
Updated recommendations on first-line and second-line …
WEBDec 21, 2018 · Update on recommendations on antiretroviral regimens for treating and preventing HIV infection: In 2016, WHO published the consolidated guidelines on the use of antiretroviral (ARV) drugs for treating and preventing HIV infection and recommended tenofovir disoproxil fumarate (TDF) + lamivudine (3TC) (or emtricitabine, FTC) + …
Guidelines for managing advanced HIV disease and rapid ... - PAHO
WEBJul 7, 2017 · Overview. The objectives of these guidelines are to provide recommendations outlining a public health approach to managing people presenting with advanced HIV disease, and to provide guidance on the timing of initiation of antiretroviral therapy (ART) for all people living with HIV.
Consolidated guidelines on the use of antiretroviral drugs for …
WEBRecommendations for a public health approach - Second edition Overview These guidelines provide guidance on the diagnosis of human immunodeficiency virus (HIV) infection, the use of antiretroviral (ARV) drugs for treating and preventing HIV infection and the care of people living with HIV. They are structured along the continuum of HIV testing, prevention, …
Pre-Exposure Prophylaxis (PrEP) - PAHO/WHO | Pan American …
WEBDec 5, 2023 · Pre-exposure prophylaxis (PrEP) is a HIV medication that when used consistently, reduces the risk of HIV infection during sex by over 90%. WHO PrEP guidelines currently recommends the use of PrEP taken daily for both men and women who are at substantial risk of acquiring HIV. Daily PrEP use provides the highest amount of …
HIV Drug Resistance - PAHO/WHO | Pan American Health …
WEBSep 21, 2023 · HIV drug resistance (HIVDR) is the ability of HIV to mutate and reproduce in the presence of antiretroviral (ARV) drugs. The consequences of drug resistance include treatment failure; the transmission of drug resistant HIV; as well as increased direct and indirect costs, for patients and health systems, due to more expensive, complex and …
Guideline on when to start antiretroviral therapy and on pre …
WEBOverview This early-release guideline makes available two key recommendations that were developed during the revision process in 2015. First, antiretroviral therapy (ART) should be initiated in everyone living with HIV at any CD4 cell count. Second, the use of daily oral pre-exposure prophylaxis (PrEP) is recommended as a prevention choice for people at …